{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:01:49Z","timestamp":1785765709420,"version":"3.56.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515010950"],"award-info":[{"award-number":["2025A1515010950"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Shenzhen High-level Hospital Construction Fund","doi-asserted-by":"publisher","award":["-"],"award-info":[{"award-number":["-"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2024YFF0507700"],"award-info":[{"award-number":["2024YFF0507700"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2024YFF0727400"],"award-info":[{"award-number":["2024YFF0727400"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82327809"],"award-info":[{"award-number":["82327809"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8257072017"],"award-info":[{"award-number":["8257072017"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20220530160213030"],"award-info":[{"award-number":["JCYJ20220530160213030"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20220531094206013"],"award-info":[{"award-number":["JCYJ20220531094206013"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Shenzhen Science and Technology Innovation Commission","doi-asserted-by":"publisher","award":["JCYJ20250604183821029"],"award-info":[{"award-number":["JCYJ20250604183821029"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Peking University Shenzhen Hospital Scientific Research Fund","doi-asserted-by":"publisher","award":["KYQD2024432"],"award-info":[{"award-number":["KYQD2024432"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose: Claudin18.2 (CLDN18.2) has emerged as a significant therapeutic target for advanced gastric cancer. In this study, we aimed to develop a 177Lu-radiolabeled anti-CLDN18.2 VHH-Fc (SN-1A01) for radioimmunotherapy in gastric cancer (GC) tumor-bearing models. Methods: Immunohistochemistry (IHC) for CLDN18.2 was performed on gastric lesions induced by tumors from 37 patients with GC, as well as in a GC patient-derived xenograft (GC-PDX) tumor and GC xenograft tumors (N87\u201318.2 and NUCG4). The SN-1A01 was conjugated with DOTA and radiolabeled using 177Lu, resulting in the formation of the radioimmunoconjugate [177Lu]Lu-DOTA\u2013SN\u20131A01. We established a safe dosage for the application of [177Lu]Lu-DOTA\u2013SN\u20131A01 and evaluated the therapeutic efficacy of a single dose in GC models. Ki67 expression levels in tumors were detected via IHC following treatment with [177Lu]Lu-DOTA\u2013SN\u20131A01. Results: IHC analysis demonstrated moderate-to-high CLDN18.2 expression in 45.9% of GC patient tumor tissues. Additionally, elevated levels of CLDN18.2 were detected in GC-PDX and N87\u201318.2 tumors, whereas lower expression was shown in NUGC4. A single dose of [177Lu]Lu-DOTA\u2013SN\u20131A01 below 300 \u03bcCi (11.1 MBq) was well tolerated. [177Lu]Lu-DOTA\u2013SN\u20131A01 significantly inhibited tumor growth and increased survival time in both GC-PDX and N87\u201318.2 models across a dose of 100 and 300 \u03bcCi. However, the tumor-suppressive effect was comparatively weaker in the NUGC4 model. Reduced Ki67 expression was evident in all [177Lu]Lu-DOTA\u2013SN\u20131A01-treated tumors. Conclusion: In preclinical studies, [177Lu]Lu-DOTA\u2013SN\u20131A01 demonstrated significant antitumor efficacy with acceptable toxicity, which indicated a strong potential for clinical translation in GC therapy.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00113","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:39:28Z","timestamp":1782920368000},"page":"4101-4111","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical\nEvaluation of 177Lu-Labeled\nAnti-CLDN18.2 VHH-Fc for Radioimmunotherapy in Gastric Cancer"],"prefix":"10.1021","volume":"23","author":[{"given":"Xiaoyan","family":"Wang","sequence":"first","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]},{"name":"Shanxi Medical University , , ,","place":["Taiyuan, China, 030001"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyi","family":"Yan","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Li","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanmian","family":"Xu","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinYuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Lab , ,","place":["Shenzhen, China, 518132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyu","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Lab , ,","place":["Shenzhen, China, 518132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Xie","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Engineering, Shenzhen Bay Lab , ,","place":["Shenzhen, China, 518132"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-0075","authenticated-orcid":true,"given":"Dawei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology , , ,","place":["Wuhan, China, 430022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Dong","sequence":"additional","affiliation":[{"name":"Peking University Shenzhen Hospital , , ,","place":["Shenzhen, China, 518036"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"3","key":"2026080309075249800_cit1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics\n2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for\n36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin"},{"issue":"8","key":"2026080309075249800_cit2","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric\ncancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"2026080309075249800_cit3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev-med-081117-043436","article-title":"Gastric Cancer Etiology\nand Management in Asia and\nthe West","volume":"70","author":"Russo","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"2026080309075249800_cit4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.21147\/j.issn.1000-9604.2020.03.02","article-title":"Immune checkpoint\ninhibitors for treatment of advanced gastric or gastroesophageal junction\ncancer: Current evidence and future perspectives","volume":"32","author":"Zhang","year":"2020","journal-title":"Chin. J. Cancer Res."},{"issue":"3","key":"2026080309075249800_cit5","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.xinn.2022.100249","article-title":"Anticancer\ndrug R&D of gastrointestinal cancer in China: Current landscape\nand challenges","volume":"3","author":"Shen","year":"2022","journal-title":"Innovation (Camb)"},{"issue":"5","key":"2026080309075249800_cit6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose Deposits\nfrom 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes:\nImplications for Radiopharmaceutical Therapy","volume":"57","author":"Hindie\u0301","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026080309075249800_cit7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s13139-017-0505-6","article-title":"Lu-177-Based Peptide Receptor Radionuclide Therapy\nfor Advanced Neuroendocrine\nTumors","volume":"52","author":"Kim","year":"2018","journal-title":"Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026080309075249800_cit8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate\nfor Midgut Neuroendocrine\nTumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"2026080309075249800_cit9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant\nProstate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"2026080309075249800_cit10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.addr.2005.01.006","article-title":"Role of claudins\nin tumorigenesis","volume":"57","author":"Swisshelm","year":"2005","journal-title":"Adv. Drug Deliv Rev."},{"issue":"1","key":"2026080309075249800_cit11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcmgh.2019.04.004","article-title":"Unraveling\na New Role for Claudins in Gastric Tumorigenesis","volume":"8","author":"Hagen","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"2026080309075249800_cit12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular\nbiomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark Res."},{"issue":"5","key":"2026080309075249800_cit13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00259-023-06561-1","article-title":"[(177)Lu]Lu-labeled\nanti-claudin-18.2\nantibody demonstrated radioimmunotherapy potential in gastric cancer\nmouse xenograft models","volume":"51","author":"Zeng","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"key":"2026080309075249800_cit14","doi-asserted-by":"publisher","first-page":"116134","DOI":"10.1016\/j.ejmech.2024.116134","article-title":"Exploration of radionuclide labeling of a novel scFv-Fc fusion protein\ntargeting CLDN18.2 for tumor diagnosis and treatment","volume":"266","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"2026080309075249800_cit15","doi-asserted-by":"publisher","first-page":"1292839","DOI":"10.3389\/fimmu.2023.1292839","article-title":"A novel nanobody-based\nHER2-targeting antibody exhibits potent synergistic\nantitumor efficacy in trastuzumab-resistant cancer cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"2026080309075249800_cit16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: Next Generation\nof Cancer Diagnostics and Therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front.\nOncol."},{"issue":"1","key":"2026080309075249800_cit17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antib8010013","article-title":"Nanobody Engineering: Toward Next\nGeneration Immunotherapies\nand Immunoimaging of Cancer","volume":"8","author":"Chanier","year":"2019","journal-title":"Antibodies"},{"key":"2026080309075249800_cit18","doi-asserted-by":"publisher","first-page":"885424","DOI":"10.3389\/fimmu.2022.885424","article-title":"Development\nof a Humanized VHH Based\nRecombinant Antibody Targeting Claudin 18.2 Positive Cancers","volume":"13","author":"Zhong","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"2026080309075249800_cit19","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1007\/s00259-022-05739-3","article-title":"Development\nand comparison of three (89)Zr-labeled anti-CLDN18.2\nantibodies to noninvasively evaluate CLDN18.2 expression in gastric\ncancer: a preclinical study","volume":"49","author":"Hu","year":"2022","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"issue":"9","key":"2026080309075249800_cit20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jpha.2023.08.007","article-title":"CLDN18.2-targeted molecular\nimaging and precision therapy of gastrointestinal tumors","volume":"13","author":"Chen","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"1","key":"2026080309075249800_cit21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-023-01406-8","article-title":"Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated\nfibroblasts drives tumor progression","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun.\nSignal"},{"issue":"12","key":"2026080309075249800_cit22","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.21873\/anticanres.13919","article-title":"Clinical\nImplications of Claudin18.2\nExpression in Patients With Gastric Cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res."},{"issue":"5","key":"2026080309075249800_cit23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","article-title":"Expression\nof the potential therapeutic target claudin-18.2 is frequently decreased\nin gastric cancer: results from a large Caucasian cohort study","volume":"475","author":"Dottermusch","year":"2019","journal-title":"Virchows Arch."},{"key":"2026080309075249800_cit24","doi-asserted-by":"publisher","first-page":"118319","DOI":"10.1016\/j.bmc.2025.118319","article-title":"Engineered\nB7-H3-targeted VHH-Fc fusion antibody demonstrates rapid tumor accumulation\nfor infrared imaging in pancreatic cancer xenograft model","volume":"129","author":"Mo","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"2026080309075249800_cit25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1021\/acs.molpharmaceut.4c01427","article-title":"Targeted Radionuclide Therapy of\nCLDN18.2-Positive Gastric Cancer with [(131)I]I-Zolbetuximab: An In\nVitro and In Vivo Study","volume":"22","author":"Wang","year":"2025","journal-title":"Mol. Pharmaceutics"},{"issue":"4","key":"2026080309075249800_cit26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jpha.2023.02.011","article-title":"Development of a CLDN18.2-targeting\nimmuno-PET probe for non-invasive imaging in gastrointestinal tumors","volume":"13","author":"Chen","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"6","key":"2026080309075249800_cit27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2967\/jnumed.123.267110","article-title":"(68)Ga-NC-BCH Whole-Body\nPET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal\nCancer Patients","volume":"65","author":"Qi","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026080309075249800_cit28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/ph15101292","article-title":"[(177)Lu]Lu-PSMA-617\n(Pluvicto(TM)): The First FDA-Approved Radiotherapeutical\nfor Treatment of Prostate Cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals\n(Basel)"},{"issue":"8","key":"2026080309075249800_cit29","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-Specific\nMembrane Antigen Radioligand Therapy\nUsing (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in Patients with Metastatic\nCastration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution,\nand Dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026080309075249800_cit30","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","article-title":"Ki67 is a promising\nmolecular target in the diagnosis of cancer (review)","volume":"11","author":"Li","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"2026080309075249800_cit31","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1021\/acs.molpharmaceut.4c01285","article-title":"Development and Characterization\nof the [(177)Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy\nin the Gastric Cancer Xenograft Model","volume":"22","author":"Mao","year":"2025","journal-title":"Mol.\nPharmaceutics"},{"issue":"8","key":"2026080309075249800_cit32","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s00259-022-05723-x","article-title":"GPC3-targeted immunoPET imaging of\nhepatocellular carcinomas","volume":"49","author":"An","year":"2022","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"issue":"7","key":"2026080309075249800_cit33","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1021\/acs.bioconjchem.2c00209","article-title":"IgG-Binding Nanobody\nCapable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life\nand Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy","volume":"33","author":"Hu","year":"2022","journal-title":"Bioconjug Chem."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00113","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4101\/65306126\/acs.molpharmaceut.6c00113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4101\/65306126\/acs.molpharmaceut.6c00113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:18:07Z","timestamp":1785763087000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4101\/5172077\/Preclinical-Evaluation-of-177Lu-Labeled-Anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00113","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}